Market Overview

UPDATE: Piper Jaffray Upgrades Alnylam Pharmaceuticals to Overweight; Overhang Removed

Share:
Related ALNY
Chardan Analysts Initiate Coverage On Akari Therapeutics With A Sell Rating
Arbutus Biopharma Taken Off Of Chardan's Sell List

Piper Jaffray raised its rating on Alnylam Pharmaceuticals (NASDAQ: ALNY) from Neutral to Overweight and increased its price target from $19 to $25.

Piper Jaffray noted, "With the Tekmira litigation behind them, Alnylam can now focus on RNAi clinical progress and partnerships in 2013. Specifically, we look forward to Phase II ALN-TTR02 data this summer to prepare the company for pivotal studies by year-end. We also expect Alnylam to file INDs on sub-cutaneous formulations of ALN-TTR02 and ALN-AT3, an innovative hemophilia therapy. We also look for Alnylam to continue to partner its RNAi therapeutic pipeline, most importantly ALN-PCS to lower cholesterol."

Alnylam Pharmaceuticals closed at $17.99 on Tuesday.

Latest Ratings for ALNY

DateFirmActionFromTo
May 2016Leerink SwannMaintainsOutperform
Apr 2016Chardan CapitalInitiates Coverage onBuy
Mar 2016JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for ALNY
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (ALNY)

View Comments and Join the Discussion!